Volume 31, Issue 4 (Avicenna Journal of Clinical Medicine-Winter 2025)
Avicenna J Clin Med 2025, 31(4): 197-205 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ali Z, Zargar A M, Mohagheghi S. Opposing Expressions of Nidogen-1 and Cdc42 Genes in the Development of Liver Cirrhosis in Patients with Non-Alcoholic Fatty Liver Disease. Avicenna J Clin Med 2025; 31 (4) :197-205
URL: http://sjh.umsha.ac.ir/article-1-3142-en.html
URL: http://sjh.umsha.ac.ir/article-1-3142-en.html
1- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran & Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
2- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran & Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,amr.mohaghegh@yahoo.com
2- Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran
3- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran & Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract: (860 Views)
Background and Objective: The roles of Nidogen-1 and Cdc42 genes as significant factors in the metabolism of the extracellular matrix have been demonstrated in the fibrosis of various tissues. This study investigates the gene expressions of Nidogen-1 and Cdc42 in the liver tissue of patients with cirrhosis, as well as in patients with simple non-alcoholic steatosis and control subjects.
Materials and Methods: In this case-control study, 38 tissue samples were collected and analyzed across three groups: cirrhosis (24 samples), simple steatosis (6 samples), and the control group (8 samples). The expression of Nidogen-1 and Cdc42 genes was investigated using RT-qPCR.
Results: The gene expressions of Nidogen-1 and Cdc42 in tissues affected by cirrhosis were significantly lower compared to the control group (P=0.001 and P=0.008, respectively). The Nidogen-1 gene exhibited the lowest expression in tissues with Nonalcoholic steatohepatitis (NASH) cirrhosis when compared to the control group, while its expression in tissues with simple steatosis fell between that of the NASH cirrhosis and control groups. Conversely, the expression of the Cdc42 gene in tissues with simple steatosis was significantly lower than in liver tissues with NASH cirrhosis (P=0.043).
Conclusion: The gene expressions of Nidogen-1 and Cdc42 decrease in cirrhosis; however, they exhibit different levels between steatosis and NASH cirrhosis. Therefore, the anti-fibrotic role of Nidogen-1 and the involvement of Cdc42 in fibrosis formation are plausible
Materials and Methods: In this case-control study, 38 tissue samples were collected and analyzed across three groups: cirrhosis (24 samples), simple steatosis (6 samples), and the control group (8 samples). The expression of Nidogen-1 and Cdc42 genes was investigated using RT-qPCR.
Results: The gene expressions of Nidogen-1 and Cdc42 in tissues affected by cirrhosis were significantly lower compared to the control group (P=0.001 and P=0.008, respectively). The Nidogen-1 gene exhibited the lowest expression in tissues with Nonalcoholic steatohepatitis (NASH) cirrhosis when compared to the control group, while its expression in tissues with simple steatosis fell between that of the NASH cirrhosis and control groups. Conversely, the expression of the Cdc42 gene in tissues with simple steatosis was significantly lower than in liver tissues with NASH cirrhosis (P=0.043).
Conclusion: The gene expressions of Nidogen-1 and Cdc42 decrease in cirrhosis; however, they exhibit different levels between steatosis and NASH cirrhosis. Therefore, the anti-fibrotic role of Nidogen-1 and the involvement of Cdc42 in fibrosis formation are plausible
Type of Study: Original |
Subject:
Clinical Biochemistry
Extended Abstract [HTM 51 KB] (79 Download)
References
1. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359-1376. PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X
2. Lădaru A, Bălănescu P, Stan M, Codreanu I, Anca IA. Candidate proteomic biomarkers for non-alcoholic fatty liver disease (steatosis and non-alcoholic steatohepatitis) discovered with mass-spectrometry: a systematic review. Biomarkers. 2016;21(2):102-14. PMID: 26632636 DOI: 10.3109/1354750X.2015.1118542
3. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969-74. PMID: 20581244 DOI: 10.1136/gut.2009.205088
4. Webb GJ, Hirschfield GM, Krawitt EL, Gershwin ME. Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annu Rev Pathol. 2018;13:247-92. PMID: 29140756 DOI: 10.1146/annurev-pathol-020117-043534
5. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis–a comprehensive review. J Hepatol. 2017;67(6):1298-323. PMID: 28802875 DOI: 10.1016/j.jhep.2017.07.022
6. Tabibian JH, Bowlus CL. Primary sclerosing cholangitis: A review and update. Liver Res. 2017;1(4):221-230. PMID: 29977644 DOI: 10.1016/j.livres.2017.12.002
7. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol. 2004;35(9):1070-82. PMID: 15343508 DOI: 10.1016/j.humpath.2004.04.017
8. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002
9. Aubé C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis.J Hepatol. 1999;30(3):472-8. PMID: 10190731 DOI: 10.1016/s0168-8278(99)80107-x
10. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-62. PMID: 16970019
11. Elias H, Bengelsdorf H. The structure of the liver of vertebrates. Acta Anat (Basel). 1952;14(4):297-337. PMID: 14943381 DOI: 10.1159/000140715
12. Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4-27. PMID: 26562801 DOI: 10.1016/j.addr.2015.11.001
13. Mak KM, Mei R. Basement Membrane Type IV Collagen and Laminin: An Overview of Their Biology and Value as Fibrosis Biomarkers of Liver Disease. Anat Rec (Hoboken). 2017;300(8):1371-90. PMID: 28187500 DOI: 10.1002/ar.23567
14. Zhou S, Chen S, Pei YA, Pei M. Nidogen: A matrix protein with potential roles in musculoskeletal tissue regeneration. Genes Dis. 2022;9(3):598-609. PMID: 35782975 DOI: 10.1016/j.gendis.2021.03.004
15. Zbinden A, Layland SL, Urbanczyk M, Carvajal Berrio DA, Marzi J, Zauner M, et al. Nidogen-1 Mitigates Ischemia and Promotes Tissue Survival and Regeneration. Adv Sci (Weinh). 2021;8(4):2002500. PMID: 33643791 DOI: 10.1002/advs.202002500
16. Rosero Salazar DH, van Rheden REM, van Hulzen M, Carvajal Monroy PL, Wagener F, Von den Hoff JW. Fibrin with Laminin-Nidogen Reduces Fibrosis and Improves Soft Palate Regeneration Following Palatal Injury. Biomolecules. 2021;11(10):1547. PMID: 34680180 DOI: 10.3390/biom11101547
17. Huang QY, Lai XN, Qian XL, Lv LC, Li J, Duan J, et al. Cdc42: A Novel Regulator of Insulin Secretion and Diabetes-Associated Diseases. Int J Mol Sci. 2019;20. PMID: 30621321 DOI: 10.3390/ijms20010179
18. Umbayev B, Saliev T, Safarova Yantsen Y, Yermekova A, Olzhayev F, Bulanin D, et al. The Role of Cdc42 in the Insulin and Leptin Pathways Contributing to the Development of Age-Related Obesity. Nutrients. 2023; 15(23):4964. PMID: 38068822 DOI: 10.3390/nu15234964
19. Ge J, Burnier L, Adamopoulou M, Kwa MQ, Schaks M, Rottner K, et al. RhoA, Rac1, and Cdc42 differentially regulate αSMA and collagen I expression in mesenchymal stem cells. J Biol Chem. 2018;293(24):9358-69. PMID: 29700112 DOI: 10.1074/jbc.RA117.001113
20. Lee NY, Suk KT. The Role of the Gut Microbiome in Liver Cirrhosis Treatment. Int J Mol Sci. 2020 ;22(1):199. PMID: 33379148 DOI: 10.3390/ijms22010199
21. Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388-98. PMID: 36977794 DOI: 10.1038/s41575-023-00759-2
22. Hasegawa S, Yoneda M, Kurita Y, Nogami A, Honda Y, Hosono K, et al. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. Drugs. 2021;81(10):1181-92. PMID: 34142342 DOI: 10.1007/s40265-021-01545-7
23. Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis. Hepatology. 2022;76(6):1862-79. PMID: 35611859 DOI: 10.1002/hep.32591
24. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 2014;20(45):16820-30. PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820
25. Saikia P, Thangavadivel S, Medeiros CS, Lassance L, de Oliveira RC, Wilson SE. IL-1 and TGF-β Modulation of Epithelial Basement Membrane Components Perlecan and Nidogen Production by Corneal Stromal Cells. Invest Ophthalmol Vis Sci. 2018;59(13):5589-98. PMID: 30480706 DOI: 10.1167/iovs.18-25202
26. Pereira BA, Ritchie S, Chambers CR, Gordon KA, Magenau A, Murphy KJ, et al. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Sci Adv. 2024;10(27):eadl1197. PMID: 38959305 DOI: 10.1126/sciadv.adl1197
27. Hu X, Gan L, Tang Z, Lin R, Liang Z, Li F, et al. A Natural Small Molecule Mitigates Kidney Fibrosis by Targeting Cdc42-mediated GSK-3β/β-catenin Signaling. Adv Sci (Weinh). 2024;11(13):e2307850. PMID: 38240457 DOI: 10.1002/advs.202307850
28. Liu D, Tian X, Liu Y, Song H, Cheng X, Zhang X, et al. CREG ameliorates the phenotypic switching of cardiac fibroblasts after myocardial infarction via modulation of CDC42. Cell Death Dis. 2021;12(4):355. PMID: 33824277 DOI: 10.1038/s41419-021-03623-w
29. Choi SY, Chacon-Heszele MF, Huang L, McKenna S, Wilson FP, Zuo X, et al. Cdc42 Deficiency Causes Ciliary Abnormalities and Cystic Kidneys. J Am Soc of Nephrol. 2013;24(9):1435-50. PMID: 23766535 DOI: 10.1681/ASN.2012121236
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
